Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Shares Outstanding (Diluted Average): 2016-2025

Historic Shares Outstanding (Diluted Average) for Anaptysbio (ANAB) over the last 6 years, with Sep 2025 value amounting to $29.1 million.

  • Anaptysbio's Shares Outstanding (Diluted Average) rose 0.66% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year increase of 0.66%. This contributed to the annual value of $28.4 million for FY2024, which is 5.42% up from last year.
  • As of Q3 2025, Anaptysbio's Shares Outstanding (Diluted Average) stood at $29.1 million, which was down 2.14% from $29.7 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Shares Outstanding (Diluted Average) ranged from a high of $30.6 million in Q1 2025 and a low of $26.8 million during Q1 2024.
  • In the last 3 years, Anaptysbio's Shares Outstanding (Diluted Average) had a median value of $28.0 million in 2023 and averaged $28.2 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first declined by 4.42% in 2023, then increased by 14.34% in 2025.
  • Over the past 5 years, Anaptysbio's Shares Outstanding (Diluted Average) (Quarterly) stood at $27.4 million in 2021, then rose by 2.68% to $28.2 million in 2022, then dropped by 4.41% to $26.9 million in 2023, then rose by 5.42% to $28.4 million in 2024, then grew by 0.66% to $29.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $29.1 million for Q3 2025, versus $29.7 million for Q2 2025 and $30.6 million for Q1 2025.